Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

AZTA vs QGEN

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
AZTA
Azenta, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$855M
5Y Perf.-53.5%
QGEN
Qiagen N.V.

Medical - Diagnostics & Research

HealthcareNYSE • NL
Market Cap$6.91B
5Y Perf.-27.8%

AZTA vs QGEN — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
AZTA logoAZTA
QGEN logoQGEN
IndustryMedical - Instruments & SuppliesMedical - Diagnostics & Research
Market Cap$855M$6.91B
Revenue (TTM)$597M$2.09B
Net Income (TTM)$-178M$425M
Gross Margin44.6%61.8%
Operating Margin-26.4%24.9%
Forward P/E23.7x13.4x
Total Debt$111M$1.65B
Cash & Equiv.$280M$839M

AZTA vs QGENLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

AZTA
QGEN
StockMay 20May 26Return
Azenta, Inc. (AZTA)10046.5-53.5%
Qiagen N.V. (QGEN)10072.2-27.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: AZTA vs QGEN

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: QGEN leads in 7 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. As sector peers, any of these can serve as alternatives in the same allocation.
AZTA
Azenta, Inc.
The Long-Run Compounder

AZTA is the clearest fit if your priority is long-term compounding.

  • 123.4% 10Y total return vs QGEN's 65.1%
Best for: long-term compounding
QGEN
Qiagen N.V.
The Income Pick

QGEN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 1 yrs, beta 0.42, yield 0.8%
  • Rev growth 5.7%, EPS growth 436.8%, 3Y rev CAGR -0.8%
  • Lower volatility, beta 0.42, Low D/E 43.8%, current ratio 3.90x
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthQGEN logoQGEN5.7% revenue growth vs AZTA's 3.6%
ValueQGEN logoQGENLower P/E (13.4x vs 23.7x)
Quality / MarginsQGEN logoQGEN20.3% margin vs AZTA's -29.9%
Stability / SafetyQGEN logoQGENBeta 0.42 vs AZTA's 2.17
DividendsQGEN logoQGEN0.8% yield; 1-year raise streak; the other pay no meaningful dividend
Momentum (1Y)QGEN logoQGEN-15.4% vs AZTA's -26.5%
Efficiency (ROA)QGEN logoQGEN7.0% ROA vs AZTA's -8.8%, ROIC 8.6% vs -0.5%

AZTA vs QGEN — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

AZTAAzenta, Inc.
FY 2025
Service
70.8%$421M
Product
29.2%$173M
QGENQiagen N.V.
FY 2025
Consumables and Related
44.9%$1.9B
Diagnostic Solutions
19.2%$803M
Sample Technologies
15.8%$661M
PCR / Nucleic Acid Amplification
7.4%$309M
Genomics / NGS
5.8%$242M
Instruments
5.1%$214M
Product and Service, Other
1.8%$75M

AZTA vs QGEN — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLQGENLAGGINGAZTA

Income & Cash Flow (Last 12 Months)

QGEN leads this category, winning 6 of 6 comparable metrics.

QGEN is the larger business by revenue, generating $2.1B annually — 3.5x AZTA's $597M. QGEN is the more profitable business, keeping 20.3% of every revenue dollar as net income compared to AZTA's -29.9%.

MetricAZTA logoAZTAAzenta, Inc.QGEN logoQGENQiagen N.V.
RevenueTrailing 12 months$597M$2.1B
EBITDAEarnings before interest/tax-$115M$714M
Net IncomeAfter-tax profit-$178M$425M
Free Cash FlowCash after capex$29M$453M
Gross MarginGross profit ÷ Revenue+44.6%+61.8%
Operating MarginEBIT ÷ Revenue-26.4%+24.9%
Net MarginNet income ÷ Revenue-29.9%+20.3%
FCF MarginFCF ÷ Revenue+4.8%+21.7%
Rev. Growth (YoY)Latest quarter vs prior year+1.0%+3.7%
EPS Growth (YoY)Latest quarter vs prior year-3.0%+26.8%
QGEN leads this category, winning 6 of 6 comparable metrics.

Valuation Metrics

Evenly matched — AZTA and QGEN each lead in 3 of 6 comparable metrics.

On an enterprise value basis, QGEN's 10.8x EV/EBITDA is more attractive than AZTA's 13.8x.

MetricAZTA logoAZTAAzenta, Inc.QGEN logoQGENQiagen N.V.
Market CapShares × price$855M$6.9B
Enterprise ValueMkt cap + debt − cash$687M$7.7B
Trailing P/EPrice ÷ TTM EPS-15.22x16.44x
Forward P/EPrice ÷ next-FY EPS est.23.68x13.42x
PEG RatioP/E ÷ EPS growth rate0.37x
EV / EBITDAEnterprise value multiple13.75x10.82x
Price / SalesMarket cap ÷ Revenue1.44x3.31x
Price / BookPrice ÷ Book value/share0.49x1.85x
Price / FCFMarket cap ÷ FCF22.32x15.24x
Evenly matched — AZTA and QGEN each lead in 3 of 6 comparable metrics.

Profitability & Efficiency

QGEN leads this category, winning 5 of 8 comparable metrics.

QGEN delivers a 11.9% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-11 for AZTA. AZTA carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to QGEN's 0.44x. On the Piotroski fundamental quality scale (0–9), QGEN scores 8/9 vs AZTA's 6/9, reflecting strong financial health.

MetricAZTA logoAZTAAzenta, Inc.QGEN logoQGENQiagen N.V.
ROE (TTM)Return on equity-10.7%+11.9%
ROA (TTM)Return on assets-8.8%+7.0%
ROICReturn on invested capital-0.5%+8.6%
ROCEReturn on capital employed-0.6%+9.5%
Piotroski ScoreFundamental quality 0–968
Debt / EquityFinancial leverage0.06x0.44x
Net DebtTotal debt minus cash-$169M$815M
Cash & Equiv.Liquid assets$280M$839M
Total DebtShort + long-term debt$111M$1.7B
Interest CoverageEBIT ÷ Interest expense15.74x
QGEN leads this category, winning 5 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

QGEN leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in QGEN five years ago would be worth $7,665 today (with dividends reinvested), compared to $1,903 for AZTA. Over the past 12 months, QGEN leads with a -15.4% total return vs AZTA's -26.5%. The 3-year compound annual growth rate (CAGR) favors QGEN at -7.5% vs AZTA's -25.8% — a key indicator of consistent wealth creation.

MetricAZTA logoAZTAAzenta, Inc.QGEN logoQGENQiagen N.V.
YTD ReturnYear-to-date-44.4%-20.7%
1-Year ReturnPast 12 months-26.5%-15.4%
3-Year ReturnCumulative with dividends-59.1%-20.7%
5-Year ReturnCumulative with dividends-81.0%-23.3%
10-Year ReturnCumulative with dividends+123.4%+65.1%
CAGR (3Y)Annualised 3-year return-25.8%-7.5%
QGEN leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

QGEN leads this category, winning 2 of 2 comparable metrics.

QGEN is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than AZTA's 2.17 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. QGEN currently trades 58.0% from its 52-week high vs AZTA's 44.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricAZTA logoAZTAAzenta, Inc.QGEN logoQGENQiagen N.V.
Beta (5Y)Sensitivity to S&P 5002.17x0.42x
52-Week HighHighest price in past year$41.73$57.82
52-Week LowLowest price in past year$17.11$33.17
% of 52W HighCurrent price vs 52-week peak+44.5%+58.0%
RSI (14)Momentum oscillator 0–10031.129.3
Avg Volume (50D)Average daily shares traded1.0M1.9M
QGEN leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

QGEN leads this category, winning 1 of 1 comparable metric.

Wall Street rates AZTA as "Buy" and QGEN as "Hold". Consensus price targets imply 140.5% upside for AZTA (target: $45) vs 41.7% for QGEN (target: $48). QGEN is the only dividend payer here at 0.78% yield — a key consideration for income-focused portfolios.

MetricAZTA logoAZTAAzenta, Inc.QGEN logoQGENQiagen N.V.
Analyst RatingConsensus buy/hold/sellBuyHold
Price TargetConsensus 12-month target$44.67$47.50
# AnalystsCovering analysts1229
Dividend YieldAnnual dividend ÷ price+0.8%
Dividend StreakConsecutive years of raises01
Dividend / ShareAnnual DPS$0.26
Buyback YieldShare repurchases ÷ mkt cap0.0%+4.4%
QGEN leads this category, winning 1 of 1 comparable metric.
Key Takeaway

QGEN leads in 5 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.

Best OverallQiagen N.V. (QGEN)Leads 5 of 6 categories
Loading custom metrics...

AZTA vs QGEN: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is AZTA or QGEN a better buy right now?

For growth investors, Qiagen N.

V. (QGEN) is the stronger pick with 5. 7% revenue growth year-over-year, versus 3. 6% for Azenta, Inc. (AZTA). Qiagen N. V. (QGEN) offers the better valuation at 16. 4x trailing P/E (13. 4x forward), making it the more compelling value choice. Analysts rate Azenta, Inc. (AZTA) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — AZTA or QGEN?

On forward P/E, Qiagen N.

V. is actually cheaper at 13. 4x.

03

Which is the better long-term investment — AZTA or QGEN?

Over the past 5 years, Qiagen N.

V. (QGEN) delivered a total return of -23. 3%, compared to -81. 0% for Azenta, Inc. (AZTA). Over 10 years, the gap is even starker: AZTA returned +123. 4% versus QGEN's +65. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — AZTA or QGEN?

By beta (market sensitivity over 5 years), Qiagen N.

V. (QGEN) is the lower-risk stock at 0. 42β versus Azenta, Inc. 's 2. 17β — meaning AZTA is approximately 420% more volatile than QGEN relative to the S&P 500. On balance sheet safety, Azenta, Inc. (AZTA) carries a lower debt/equity ratio of 6% versus 44% for Qiagen N. V. — giving it more financial flexibility in a downturn.

05

Which is growing faster — AZTA or QGEN?

By revenue growth (latest reported year), Qiagen N.

V. (QGEN) is pulling ahead at 5. 7% versus 3. 6% for Azenta, Inc. (AZTA). On earnings-per-share growth, the picture is similar: Qiagen N. V. grew EPS 436. 8% year-over-year, compared to 60. 5% for Azenta, Inc.. Over a 3-year CAGR, AZTA leads at 2. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — AZTA or QGEN?

Qiagen N.

V. (QGEN) is the more profitable company, earning 20. 3% net margin versus -9. 4% for Azenta, Inc. — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QGEN leads at 24. 9% versus -1. 9% for AZTA. At the gross margin level — before operating expenses — QGEN leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is AZTA or QGEN more undervalued right now?

On forward earnings alone, Qiagen N.

V. (QGEN) trades at 13. 4x forward P/E versus 23. 7x for Azenta, Inc. — 10. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AZTA: 140. 5% to $44. 67.

08

Which pays a better dividend — AZTA or QGEN?

In this comparison, QGEN (0.

8% yield) pays a dividend. AZTA does not pay a meaningful dividend and should not be held primarily for income.

09

Is AZTA or QGEN better for a retirement portfolio?

For long-horizon retirement investors, Qiagen N.

V. (QGEN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 42), 0. 8% yield). Azenta, Inc. (AZTA) carries a higher beta of 2. 17 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (QGEN: +65. 1%, AZTA: +123. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between AZTA and QGEN?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AZTA is a small-cap quality compounder stock; QGEN is a small-cap deep-value stock. QGEN pays a dividend while AZTA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

AZTA

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 26%
Run This Screen
Stocks Like

QGEN

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 12%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform AZTA and QGEN on the metrics below

Revenue Growth>
%
(AZTA: 1.0% · QGEN: 3.7%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.